EP0822984A4 - Rezeptor für humanen tumor nekrosis faktor - Google Patents

Rezeptor für humanen tumor nekrosis faktor

Info

Publication number
EP0822984A4
EP0822984A4 EP95917662A EP95917662A EP0822984A4 EP 0822984 A4 EP0822984 A4 EP 0822984A4 EP 95917662 A EP95917662 A EP 95917662A EP 95917662 A EP95917662 A EP 95917662A EP 0822984 A4 EP0822984 A4 EP 0822984A4
Authority
EP
European Patent Office
Prior art keywords
men
necrosis factor
tumor necrosis
factor receptors
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP95917662A
Other languages
English (en)
French (fr)
Other versions
EP0822984A1 (de
Inventor
Jian Ni
Reiner Gentz
Craig A Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to EP08013946A priority Critical patent/EP2017337A1/de
Publication of EP0822984A1 publication Critical patent/EP0822984A1/de
Publication of EP0822984A4 publication Critical patent/EP0822984A4/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP95917662A 1995-04-27 1995-04-27 Rezeptor für humanen tumor nekrosis faktor Ceased EP0822984A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08013946A EP2017337A1 (de) 1995-04-27 1995-04-27 Rezeptoren für den menschlichen Tumornekrosefaktor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1995/005058 WO1996034095A1 (en) 1995-04-27 1995-04-27 Human tumor necrosis factor receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP08013946A Division EP2017337A1 (de) 1995-04-27 1995-04-27 Rezeptoren für den menschlichen Tumornekrosefaktor

Publications (2)

Publication Number Publication Date
EP0822984A1 EP0822984A1 (de) 1998-02-11
EP0822984A4 true EP0822984A4 (de) 2000-05-03

Family

ID=22249014

Family Applications (2)

Application Number Title Priority Date Filing Date
EP08013946A Withdrawn EP2017337A1 (de) 1995-04-27 1995-04-27 Rezeptoren für den menschlichen Tumornekrosefaktor
EP95917662A Ceased EP0822984A4 (de) 1995-04-27 1995-04-27 Rezeptor für humanen tumor nekrosis faktor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP08013946A Withdrawn EP2017337A1 (de) 1995-04-27 1995-04-27 Rezeptoren für den menschlichen Tumornekrosefaktor

Country Status (4)

Country Link
EP (2) EP2017337A1 (de)
JP (1) JPH11507205A (de)
AU (1) AU2363695A (de)
WO (1) WO1996034095A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852173A (en) * 1994-10-19 1998-12-22 Genetics Institute, Inc. TNF receptor death ligand proteins and inhibitors of ligand binding
US5712381A (en) 1994-10-19 1998-01-27 Genetics Institute, Inc. MADD, a TNF receptor death domain ligand protein
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6291207B1 (en) 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
EP0961782A4 (de) * 1996-10-30 2003-07-16 Human Genome Sciences Inc Rezeptor tr2 aus der tumornekrosisfaktor-rezeptor-familie.
AU5516898A (en) * 1996-12-12 1998-07-03 Genentech Inc. Hvem polypeptides and uses thereof
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
PT951551E (pt) 1996-12-23 2008-10-28 Immunex Corp Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
DE69837996T2 (de) 1997-01-14 2008-02-28 Human Genome Sciences, Inc. Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
US6013476A (en) * 1997-04-02 2000-01-11 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor TR7
EP0869179A1 (de) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation Mit Tumor - Nekrose zusammenhängender Rezeptor, TR7
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
WO1998051346A1 (en) * 1997-05-12 1998-11-19 Smithkline Beecham Corporation Human tumor necrosis factor receptor-like 2 (tr2) antibodies
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US6346388B1 (en) 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
EP1076699B1 (de) 1998-05-14 2008-10-29 Immunex Corporation Verfahren zur hemmung der wirkung der osteoklasten
JP2002529051A (ja) * 1998-09-03 2002-09-10 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヘルペスウイルス侵入メディエーター関連タンパク質ファミリーの新規分子およびその使用
US6287808B1 (en) 1998-09-03 2001-09-11 Millennium Pharmaceuticals, Inc. Molecules of the herpesvirus-entry-mediator-related protein family and uses thereof
EP2357192A1 (de) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
EP1274720A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin enthaltende fusionsproteine
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
CN100594935C (zh) 2001-05-25 2010-03-24 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
US20030068619A1 (en) * 2001-07-27 2003-04-10 Lal Preeti G. TNF receptor 2 related protein variant
WO2003011321A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of cobesin for the treatment of metabolic disorders
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
EP1786463A4 (de) 2004-03-26 2009-05-20 Human Genome Sciences Inc Antikörper gegen nogo-rezeptor
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
CN105624193B (zh) 2008-09-26 2021-07-13 索元生物医药(美国)有限公司 重组载体
CN102770458A (zh) 2009-12-02 2012-11-07 阿塞勒隆制药公司 用于增加Fc融合蛋白的血清半寿期的组合物和方法
AU2011323784A1 (en) 2010-10-25 2013-05-30 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
AR084141A1 (es) 2010-11-19 2013-04-24 Imai Toshio Anticuerpos neutralizadores anti-ccl20
EP2718328A4 (de) 2011-06-08 2014-12-24 Acceleron Pharma Inc Zusammensetzungen und verfahren zur erhöhung der halbwertszeit von serum
US11065311B2 (en) 2012-10-25 2021-07-20 Denovo Biopharma Llc Retroviral vector with mini-promoter cassette

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393438A2 (de) * 1989-04-21 1990-10-24 Synergen, Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393438A2 (de) * 1989-04-21 1990-10-24 Synergen, Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARMITAGE R.: "Tumor necrosis factor receptor superfamily members and their ligands", CURRENT OPINION IN IMMUNOLOGY, vol. 6, 1994, pages 407 - 413, XP024016736, DOI: doi:10.1016/0952-7915(94)90119-8 *
C A SMITH ET AL: "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 248, no. 248, 25 May 1990 (1990-05-25), pages 1019 - 1022-1023, XP002107350, ISSN: 0036-8075 *
KWON B S ET AL: "A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1997 MAY 30) 272 (22) 14272-6., XP002131224 *
See also references of WO9634095A1 *

Also Published As

Publication number Publication date
EP0822984A1 (de) 1998-02-11
EP2017337A1 (de) 2009-01-21
WO1996034095A1 (en) 1996-10-31
AU2363695A (en) 1996-11-18
JPH11507205A (ja) 1999-06-29

Similar Documents

Publication Publication Date Title
AU2363695A (en) Human tumor necrosis factor receptors
EP0777497A4 (de) Menschliche, das hiv-virus neutralisierende, monoklonale antikörper
EP1007562A4 (de) Tomornekrosefaktorrezeptor verwandte proteine tango-63d und tango-63e
EP0797447A4 (de) Heterozyklische pentapeptitische und halophenyl amide als hemmer für menschlichen krebs
EE04293B1 (et) Stabiilsed lüofiliseeritud ravimvormid
BR9701851A (pt) Poliamidoaminas altamente ramificadas e sua preparação
EP1025228A4 (de) Menschliche, dem tumor-nekrosis-faktor rezeptor ähnliche proteine tr11, tr11sv1 und tr11sv2
EP0953039A4 (de) Tiermodelle für die menschliche prostatakrebsfortschreitung
BR9407575A (pt) Recombinaçao il4 de anticorpos uteis no tratamento de desordens do il4
FI972919A7 (fi) Indolijohdannaisia jotka ovat käyttökelpoisia osteoporoosin hoidossa
ZA952587B (en) Human tumor necrosis factor receptor
AU7705098A (en) Human tumor necrosis factor receptor-like protein 8
FR2722681B1 (fr) Calecon pour homme
EP1097199A4 (de) 71 humane sekretierte proteine
EP0961782A4 (de) Rezeptor tr2 aus der tumornekrosisfaktor-rezeptor-familie.
DE69634489D1 (de) Adenovirus dodekahedrischer proteinkomplex, dieser enthaltende zusammensetzung und verwendungen davon
DE59604270D1 (de) Selbstfahrender Mähdrescher mit verstellbarem Dreschkorb
EP1159286A4 (de) Tumornekrosefaktor-rezeptoren 6 alpha und 6 beta
AU1541699A (en) Human tumor necrosis factor-r2-like proteins
EP1009431A4 (de) Antikörper gegen den menschlichen tumornekrosefaktor-rezeptor des typs 2 (tr2)
DE69603701D1 (de) Wergwerfwindel mit taillenpolster
NO980375D0 (no) Humant MP52 Arg protein
EP0804546A4 (de) Menschliche, prostata-spezifische reduktase
ATE186559T1 (de) Leukoindigo-präparationen in granulatform
AU4068897A (en) Human induced tumor protein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000316

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030425

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20080827